Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gevokizumab - XOMA/Novartis

Next Previous
Drug Profile

Gevokizumab - XOMA/Novartis

Alternative Names: S-78989; VPM 087; XMA-005.2; XMA-0052; XOMA-052

Latest Information Update: 19 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator XOMA
  • Developer IRIS; National Eye Institute; North Shore-Long Island Jewish Health System; Novartis; Servier; University of Zurich; XOMA
  • Class Antiacnes; Antineoplastics; Antirheumatics; Cardiovascular therapies; Eye disorder therapies; Immunotherapies; Vascular disorder therapies
  • Mechanism of Action Interleukin 1 beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pyoderma; Uveitis; Behcet's syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Uveitis
  • Phase II Acne vulgaris; Acute coronary syndromes; Colorectal cancer; Diabetic nephropathies; Giant cell arteritis; Labyrinthitis; Myositis; Osteoarthritis; Schnitzler syndrome; Scleritis
  • Phase I Gastric cancer; Oesophageal cancer; Renal cell carcinoma
  • Suspended Rheumatoid arthritis
  • No development reported Cancer; Gout; Juvenile rheumatoid arthritis; Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Discontinued Pyoderma

Most Recent Events

  • 19 Feb 2024 Gevokizumab is still in phase I development in Colorectal cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in Czech Republic, Japan, Singapore and UK (IV) (NCT03798626)
  • 19 Feb 2024 Gevokizumab is still in phase I development in Gastric-cancer(Combination therapy, Metastatic disease, Second-line therapy or greater) in Czech Republic, Japan, Singapore and UK (IV) (NCT03798626)
  • 19 Feb 2024 Gevokizumab is still in phase I development in Oesophageal cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in Czech Republic, Japan, Singapore and UK (IV) (NCT03798626)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top